Company: CERO
Filing Date: 2025-05-02
Form Type: PRER14A
Source: 0001213900-25-039149
Chunk: 37

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-02
Form: PRER14A
Chunk 37
---
 to include a proposal to approve this proposal at a subsequent meeting of stockholders. In the event that stockholder approval is not obtained at such subsequent meeting, the Company must cause additional meetings of stockholders to be held semi -annuallythereafter until such approval is obtained. The Company would bear the costs associated with including this proposal for stockholder approval at subsequent stockholder meetings. Vote Required; Board Recommendation The affirmative vote of the holders of a majority of the votes cast at the Annual Meeting will be required to approve this proposal. Abstentions and broker non -voteswill have no effect on the outcome of this proposal.

| THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE ISSUANCE OF SHARES OF COMMON STOCK, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635, UPON THE EXERCISE OF FEBRUARY 2025 COMMON WARRANTS AT AN EXERCISE PRICE BELOW THE MINIMUM PRICE. |     | ü |

18 PROPOSAL NO. 3: NASDAQ STOCK ISSUANCE (SERIES D) PROPOSAL Overview As described in more detail below, in April 2025, the Company issued an aggregate of 6,250shares of Series D Preferred Stock in the April 2025 Private Placement (the “April 2025 Private Placement”) and agreed to issue up to 3,750 additional shares of Series D Preferred Stock at one or more additional closings, at the election of the investors in such transaction. The Common Stock is listed on the Nasdaq Capital Market, and, as such, the Company is subject to the applicable rules of Nasdaq, including Nasdaq Listing Rules 5635(b) and 5635(d). Nasdaq Listing Rule 5635(b) requires the Company to obtain stockholder approval prior to certain issuances with respect to Common Stock or securities convertible into Common Stock which could result in a change of control of the issuer. Generally, Nasdaq interpretations provide that the acquisition of 20% of the shares of an issuer by one person or group of affiliated persons may be considered a change of control of such issuer. Nasdaq Listing Rule 5635(d) requires the Company to obtain stockholder approval prior to certain issuances with respect to Common Stock or securities convertible into Common Stock other than in a public offering if the price is below the “Minimum Price” (as determined in accordance with Nasdaq rules) in an amount greater than or equal to 20% of the number of shares of Common